In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
-
The Irish Times Business Person of the Month: Steve Cutler
ICON CEO Steve Cutler has been chosen as The Irish Times Business Person of the Month for February 2021.
-
US Regulators question AstraZeneca vaccine trial data
ICON's Dr. Andrew Garrett, Executive Vice President of Scientific Operations, weighs in on potential safety issues with the AstraZeneca COVID-19 vaccine.
-
What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer / BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
-
International Women's Day: An interview with Cindy Spittle
In this interview, Cindy Spittle talks about the women role models who provided inspiration in her career in honour of International Women's Day.
-
International Women's Day: An interview with Marelise Epstein
Marelise Epstein is interviewed for International Women's Day and provides a glimpse into her work day and what inspires her.
-
Steve Cutler: ‘People understand what a clinical trial is now’
An interview with CEO Steve Cutler on ICON's recent acquisition of PRA Health Sciences.
-
Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’
An article featuring commentary from Dr. Nuala Murphy on ICON’s learnings from conducting the Pfizer/BioNTech trial.
-
Mind the gap: Managed access programmes as an alternative to long-term follow up studies
Veronica Gutierrez Martinez and Michael Tokar discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.
-
Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.
